DOXORUBICIN IN COMBINATION WITH VERAPAMIL IN ADVANCED COLORECTAL-CANCER - A PHASE-II TRIAL

被引:15
作者
DALMARK, M
PALS, H
JOHNSEN, AH
机构
[1] RIGSHOSP,FINSEN INST,DEPT ONCOL ONA,DK-2100 COPENHAGEN,DENMARK
[2] RIGSHOSP,FINSEN INST,DEPT CLIN CHEM,DK-2100 COPENHAGEN,DENMARK
[3] AMTSSYGEHUSET GENTOFTE,DEPT HEPATOL F,DK-2900 HELLERUP,DENMARK
关键词
COLORECTAL CARCINOMA; CHEMOTHERAPY; DOXORUBICIN; VERAPAMIL;
D O I
10.3109/02841869109091808
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The possibility that verapamil might increase the sensibility of colorectal carcinomas to doxorubicin was studied in 24 patients without previous cytotoxic chemotherapy. The treatment started with oral verapamil, which was escalated up to the individual maximum tolerable dose (defined by prolongation of P-Q in ECG, fall in blood pressure, or dizziness). The median maximum tolerable dose was 600 mg (range 320-1 440 mg). During continued verapamil administration the patients then got weekly infusions of doxorubicin, 25 mg/m2. The median number of doxorubicin courses was 8 (range 2-22). Among 21 patients evaluable for response and toxicity two partial remissions occurred but no complete remission. The study did not indicate enhanced cardiac, hematological or non-hematological toxicity from the combined treatment.
引用
收藏
页码:23 / 26
页数:4
相关论文
共 21 条
[1]   CYTOFLUORESCENCE LOCALIZATION OF ADRIAMYCIN IN RESISTANT COLON CANCER-CELLS [J].
CHAUFFERT, B ;
MARTIN, F ;
CAIGNARD, A ;
JEANNIN, JF ;
LECLERC, A .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1984, 13 (01) :14-18
[2]  
CORBETT TH, 1977, CANCER, V40, P2660, DOI 10.1002/1097-0142(197711)40:5+<2660::AID-CNCR2820400940>3.0.CO
[3]  
2-M
[4]   ACTIVE OUTWARD TRANSPORT OF DAUNOMYCIN IN RESISTANT EHRLICH ASCITES TUMOR-CELLS [J].
DANO, K .
BIOCHIMICA ET BIOPHYSICA ACTA, 1973, 323 (03) :466-483
[5]  
DOUBLE JA, 1975, CANCER CHEMOTH REP 1, V59, P1083
[6]  
FINE RL, 1984, P AN M AM SOC CLIN, V3, P154
[7]  
FRYTAK S, 1975, CANCER CHEMOTH REP 1, V59, P405
[8]  
GOODMAN GE, 1987, CANCER RES, V47, P2295
[9]  
INABA M, 1979, CANCER RES, V39, P2200
[10]   TUMOR-CELL RESISTANCE TO ANTHRACYCLINES - A REVIEW [J].
KAYE, S ;
MERRY, S .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1985, 14 (02) :96-103